With its $74 billion acquisition of Celgene set to be final later this year, Bristol-Myers Squibb announced Tuesday its new executive lineup, giving an idea of how it is restructuring the commercial and research operations of the combined company.
One notable absence from the roster: Chief Scientific Officer Dr. Tom Lynch, the pioneering oncologist who joined the company in March 2017. Bristol said that Lynch will depart by Oct. 1 to “pursue opportunities in healthcare.”
About the Author Reprints
